In this trial, tofacitinib was found to be not only safe but also improve cardiometabolic and immunologic parameters including high-density lipoprotein cholesterol levels, decreasing type I IFN signature and circulating neutrophil extracellular traps (NETs), especially in the subgroup of patients with the STAT4 risk allele.48 In clinical practice, tofacitinib led to rapid remission seven out of ten patients with active skin and/or musculoskeletal disease.49 Interestingly, tofacitinib led to significant clinical improvement in 3 patients with recalcitrant cutaneous SLE.50 The gene discussed is STAT4; the disease is systemic lupus erythematosus.